MRSN Live signals | Maximize Profits with Getagraph.com

BUY 91129 min ago

@ $3.79

Issued: 14 Feb 2024 @ 13:46

Return: -7.12%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: -3.33 %

Live Chart Being Loaded With Signals

Commentary (17 Apr 2024 @ 16:00):

Stats
Today's Volume	2.60M
Average Volume	2.14M
Market Cap	424.45M
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-0.180 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.00
ATR14	$0.00900 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Alleva Lawrence M	Buy	3 996	Stock Option (right to buy)
2024-01-13	Mandelia Ashish	Buy	0
2024-01-15	Protopapas Anna	Buy	17 708	Common Stock
2024-01-15	Protopapas Anna	Buy	21 250	Common Stock
2024-01-16	Protopapas Anna	Sell	29 399	Common Stock

INSIDER POWER
74.94
Last 98 transactions
Buy: 4 017 838 \| Sell: 585 969

Volume Correlation

Long: -0.13 (neutral)

Short: 0.65 (weak)

Signal:(63.44) Neutral

Mersana Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mersana Therapeutics Inc Correlation - Currency/Commodity

-0.29
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.21
( neutral )

0.00
( neutral )

0.01
( neutral )

Mersana Therapeutics Inc Financials

Annual	2023
Revenue:	$36.86M
Gross Profit:	$35.34M (95.88 %)
EPS:	$-1.480

Q4	2023
Revenue:	$10.70M
Gross Profit:	$10.25M (95.82 %)
EPS:	$-0.160

Q3	2023
Revenue:	$7.70M
Gross Profit:	$7.27M (94.45 %)
EPS:	$-0.350

Q2	2023
Revenue:	$10.65M
Gross Profit:	$10.33M (96.96 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.